Other languages Bristol-Myers Squibb Company Sao Paulo

Equities

BMYB34

BRBMYBBDR000

Market Closed - Sao Paulo Other stock markets 09:18:13 28/06/2024 pm IST			5-day change	1st Jan Change
233 ^BRL	+1.74%		+2.42%	-6.77%

27/06	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
26/06	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Bristol Myers : approbation accélérée en cancer colorectal	24/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	22/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey	20/06
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	19/06
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06
Bristol Myers : dividendes décidés par le conseil	18/06
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06
Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST